The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences
- PMID: 16564675
- PMCID: PMC2649951
- DOI: 10.1016/j.jvoice.2006.01.007
The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences
Abstract
Objectives/hypothesis: The purpose of this study is to examine the psychosocial consequences of BOTOX (Allergan, Inc. Irvine, CA) treatment for spasmodic dysphonia (SD). This article also explores how patients judge the success of treatment and make decisions about future treatment based on psychosocial issues relevant to them.
Study design: This study follows the phenomenological tradition of qualitative inquiry in which the objective is to explore the lived experiences of a group of persons who share a common phenomenon, in this case receiving BOTOX injections for SD.
Methods: Six adults with SD who had been receiving BOTOX injections on a long-term basis participated in face-to-face interviews. The interviews were recorded, transcribed, and analyzed according to phenomenological guidelines to identify consistent themes as well as differences among participants' experiences.
Results: The results are summarized in three primary themes that suggest (1) participants' experiences vary over time based on changes in factors such as lifestyle and personal priorities; (2) BOTOX has multidimensional psychosocial implications in physical, personal, and social domains; and (3) participants individualize their treatment regimens, taking into consideration the burden of treatment, scheduling priorities, and other strategies to maximize the benefits of BOTOX.
Conclusions: Based on this study, suggestions are provided for future research into a psychosocial outcome measurement, including longitudinal evaluations that accommodate changing patient priorities over time; multidimensional evaluations that incorporate physical, personal, and social issues; evaluations that include a measure of the burden of treatment; and evaluations that support a shared decision-making model with the voice clinicians.
References
-
- National Spasmodic Dysphonia Association. [Accessed July 26, 2004]. Available at: http://www.dysphonia.org/nsda.
-
- Duffy JR, Yorkston KM. Medical interventions for spasmodic dysphonia and some related conditions: a systematic review. J Med Speech-Lang Pa. 2003;11:ix–lviii.
-
- Zwirner P, Murry T, Swenson M, Woodson GE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscape. 1992;102:400–406. - PubMed
-
- Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg. 2001;127:393–399. - PubMed
-
- Langeveld TPM, van Rossum M, Houtman EH, Zwinderman AH, Briaire JJ, Baatenburg de Jong RJ. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol. 2001;110:627–634. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
